Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Buprenorphine

FDA-approved product (film, extended release, transdermal), marketed as Brixadi, Buprenorphine, Butrans and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Buprenorphine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic pain
  • Drug dependence
  • Opioid dependence
  • Opioid use disorder
  • Overdose
  • Pain
  • Substance abuse

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Oripavine derivatives; Drugs used in opioid dependence
FDA pharmacologic class
Partial Opioid Agonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Buprenorphine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not docked: the structure could not be prepared for dockingdetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not docked: the structure could not be prepared for dockingdetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not docked: the structure could not be prepared for dockingdetails

Dihydrofolate reductase ↗ (MRSA)

Not docked: the structure could not be prepared for dockingdetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Buprenorphine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2

    NCT00015041 · start 1996-11

    Registered record
    Registry ID
    NCT00015041
    Conditions
    Opioid-Related Disorders; Substance-Related Disorders
    Interventions
    Buprenorphine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1996-11
    Completion
    1998-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-Related Disorders; Substance-Related Disorders
    InterventionBuprenorphine
    PhasePhase 1
    Registry statusCompleted

  • Alternate-Day Buprenorphine Administration. Phase II - 4

    NCT00000222 · start 1992-07

    Registered record
    Registry ID
    NCT00000222
    Conditions
    Opioid-Related Disorders
    Interventions
    Buprenorphine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1992-07
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-Related Disorders
    InterventionBuprenorphine
    PhasePhase 1
    Registry statusCompleted

  • Alternate-Day Buprenorphine Administration. Phase I - 3

    NCT00000221 · start 1992-04

    Registered record
    Registry ID
    NCT00000221
    Conditions
    Opioid-Related Disorders
    Interventions
    Buprenorphine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1992-04
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-Related Disorders
    InterventionBuprenorphine
    PhasePhase 1
    Registry statusCompleted

  • Buprenorphine Maintenance for Opioid Addicts - 2

    NCT00000203 · start 1988-08

    Registered record
    Registry ID
    NCT00000203
    Conditions
    Opioid-Related Disorders
    Interventions
    Buprenorphine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1988-08
    Completion
    2006-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-Related Disorders
    InterventionBuprenorphine
    PhasePhase 2
    Registry statusCompleted

  • Study Comparing Liquid and Tablet Buprenorphine Formulations - 5

    NCT00000302

    Registered record
    Registry ID
    NCT00000302
    Conditions
    Heroin Dependence
    Interventions
    Buprenorphine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeroin Dependence
    InterventionBuprenorphine
    PhasePhase 3
    Registry statusCompleted